Key result
High baseline urinary 11-dehydro-thromboxane B2 levels predicted 1-year major adverse cardiac events in men but not in women.
Why the study?
Despite females having higher risk of MACE and poor prognosis after PTCA, few studies have evaluated sex differences in urinary dh-TxB2 concentration for aspirin non-responsiveness.
Does gender and urinary 11-dehydro-thromboxane B2 level predict major adverse cardiac events in patients with acute coronary syndrome after percutaneous coronary intervention?
Observational (n=192)
No
Does gender and urinary 11-dehydro-thromboxane B2 level predict major adverse cardiac events in patients with acute coronary syndrome after percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Females with ACS undergoing PCI have higher baseline urinary 11-dehydro-thromboxane B2 levels than males, but high levels were significantly associated with 1-year MACE only in males.
Despite knowing that females are at a higher risk of major adverse cardiac events (MACE) and poor prognosis after percutaneous transluminal coronary angioplasty (PTCA), there are very few studies focusing on urinary 11-dehyrdothromboxane B2 (dh-TxB2) concentration (for aspirin non-responsiveness) differences among males and females.The present prospective observational study aimed to evaluate the dh-TxB2 levels and associate them with clinical outcomes in males and females with acute coronary syndrome (ACS) after PTCA.The dh-TxB2 ELISA assay was carried out twice, at baseline and 6 months follow-up, and outcomes were assessed for 1 year.The average cut-off value of dh-TxB2 was ≥1,496 pg/mg creatinine by the receiver operating characteristic curve estimation.A total of 192 patients (140 men and 52 women) were enrolled.At baseline, 17 (12.1%)males and 7 (13.5%)females had high dh-TxB2 levels, whereas at 6 months, 22 (15.9%)males and 4 (7.8%)females showed high dh-TxB2 levels.The concentration of dh-TxB2 was higher in females than males at baseline.Composite MACE was not different between genders significantly even when the dh-TxB2 levels were high.Women experienced higher MACE incidences than men (13.5% vs. 9.3%).
No takes yet. Share an insight, caveat, or question.
Sheetal et al. (2020) conducted an observational in Acute coronary syndrome (n=192). High baseline urinary 11-dehydro-thromboxane B2 (≥1,496 pg/mg Cr) vs. Normal/low urinary 11-dehydro-thromboxane B2 was evaluated on 1-year Major Adverse Cardiac Events (MACE) in males (OR 8.67, 95% CI 2.99-25.09, p=<0.001). High baseline urinary 11-dehydro-thromboxane B2 levels predicted 1-year major adverse cardiac events in men but not in women.
Synapse has enriched 10 related papers. Consider them for comparative context: